Halozyme Therapeutics, Inc. (HALO) Financial Statements

Halozyme Therapeutics, Inc.

HALO · Nasdaq

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$1.40B	$1.02B	$829.25M	$660.12M	$443.31M	$267.59M	$195.99M	$151.86M
Cost of Revenue	$228.77M	$159.42M	$192.36M	$139.30M	$81.41M	$43.37M	$45.55M	$10.14M
Research & Development	—	$79.05M	$76.36M	$66.61M	$35.67M	$34.24M	$140.80M	$150.25M
Selling, General & Administrative	$207.09M	$154.34M	$149.18M	$143.53M	$50.32M	$45.74M	$77.25M	$60.80M
Operating Expenses	$927.61M	$463.85M	$491.68M	$392.58M	$167.41M	$123.34M	$263.60M	$221.19M
Operating Income	$469.01M	$551.48M	$337.57M	$267.53M	$275.90M	$144.25M	-$67.61M	-$69.33M
Interest Expense	—	—	$18.76M	$16.95M	$7.53M	$20.38M	$11.63M	$18.04M
Other Income / (Expense)	$21.47M	$23.75M	$16.32M	$1.05M	$1.10M	$5.42M	$6.99M	$7.58M
Income Before Taxes	$466.88M	$557.13M	$348.33M	$248.92M	$248.52M	$129.30M	-$72.25M	-$79.79M
Provision for Income Taxes	$149.99M	$113.04M	$66.73M	$46.79M	-$154.19M	$217.00K	-$11.00K	$537.00K
Net Income	$316.89M	$444.09M	$281.59M	$202.13M	$402.71M	$129.09M	-$72.24M	-$80.33M
Basic EPS	$2.64	$3.50	$2.13	$1.48	$2.86	$0.95	-$0.50	-$0.56
Diluted EPS	$2.56	$3.43	$2.10	$1.44	$2.74	$0.91	-$0.50	-$0.56
Basic Shares Outstanding	119.84M	126.83M	131.93M	136.84M	140.65M	136.21M	144.33M	143.60M
Diluted Shares Outstanding	123.90M	129.42M	134.20M	140.61M	146.80M	141.46M	144.33M	143.60M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$8.31	$8.24	$8.42	3	↑0 ↓0
Dec 2027	$9.79	$9.01	$10.71	3	↑0 ↓0
Dec 2028	$10.92	$10.06	$11.78	2	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: HALO
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon and Surf Bio's hyperconcentration technology, recently renamed as Aerocon.

Key Issues

Bullish view

Strong royalty growth and record revenue growth support the view that Halozyme’s asset-light model can continue expanding earnings and cash generation.

Bearish view

Simply Wall St. argues that the stock could be overvalued despite strong royalty growth, implying that expectations and valuation may already discount substantial future expansion.

Analyst Consensus

See all

Buy

13 analysts

$129

Current

—

Low

$100

Average

—

High

Average target implies -22.22% versus the current price.

Earnings History

BeatMissNo estimate

Halozyme Therapeutics, Inc.

Analyst Estimates

Peers